The benzodiazepine deprescribing paradox: when the right answer is “don’t taper”

Benzodiazepines have a Boxed Warning — the FDA’s most prominent safety label — covering abuse, addiction, dependence, and withdrawal. Health plans now track a HEDIS measure for deprescribing benzodiazepines in older adults. Deprescribing is, by every formal signal, the right direction.

And then there’s the 2023 cohort finding that keeps surfacing in clinical reviews: long-term, stable patients who were deprescribed benzodiazepines had higher mortality, more nonfatal overdoses, more suicidal ideation, and more emergency-department visits than matched patients who continued treatment. A new April 2026 review article in GlobalRPH puts it bluntly: there is no standard schedule, no one-size-fits-all answer, and the population most clearly harmed by forced cessation is not the same population most clearly harmed by long-term use.

What the current consensus actually says

For older adults on long-term benzodiazepine therapy, recent guidelines suggest a slow, individualized taper: 20–25% of the dose for the first step, held for two to four weeks, then 5–12.5% steps with similar holds. Patient-directed approaches — where the person tapering controls the pace and has access to counseling and clinician check-ins — show cessation rates of 60–80% in the literature, compared with 10–20% under usual care.

The two clinical signals that most strongly argue against a taper are: (1) long-term stability with no escalation, no off-prescription use, and no co-prescribed opioids, and (2) a documented anxiety or seizure disorder for which the benzodiazepine is the controlled-on therapy.

The two signals most strongly argue for a taper: (1) co-prescribed opioids, especially in older adults, and (2) escalating use, sourcing outside the prescription, or signs of a use disorder.

Why this matters for people in recovery

If you are on long-term benzodiazepines and reading public-health guidance about deprescribing, the right question is not “should I stop?” — it is “what does my situation look like, and what taper, if any, fits it?” The honest answer can be no taper. It can also be a six-month, clinician-supervised, patient-directed taper. The 2023 mortality finding is a warning against blanket policy, not against deprescribing as a category.

If you are supporting someone who’s been told to stop benzodiazepines on a tight timeline by a prescriber unfamiliar with their history, ask whether a slower or patient-directed approach is on the table. Withdrawal from benzodiazepines is one of the few that can be life-threatening; abrupt cessation is rarely the right move outside of medical detox.

Find a clinician experienced with benzodiazepine tapering →